

12

EUROPEAN PATENT APPLICATION

Application number: **86305995.2**

Date of filing: **04.08.86**

Int. Cl.³: **C 07 K 5/06**
C 07 K 5/02, C 07 K 1/00
C 07 C 125/065, C 07 C 129/12
C 07 D 307/62, A 61 K 37/62

Priority: **09.08.85 US 764168**
30.04.86 US 858324

Date of publication of application:
04.03.87 Bulletin 87/10

Date of deferred publication of search report: **15.11.89**

Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

Applicant: **PFIZER INC.**
235 East 42nd Street
New York, N.Y. 10017(US)

Inventor: **Bindra, Jasjit Singh**
81, Eastwood Road
Groton Connecticut(US)


Inventor: **Rosati, Robert Louis**
Box 66A, Deans Mill Road
Stonington Connecticut(US)

Inventor: **Kleinman, Edward Fox**
544A Shennecossett Road
Groton Connecticut(US)

Representative: **Moore, James William, Dr.**
Pfizer Limited Ramsgate Road
Sandwich Kent CT13 9NJ(GB)

54 Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues.

57 Polypeptide derivatives containing 5-amino-2,
 5-disubstituted-4-hydroxypentanoic acid residues are of the
 formula:



wherein, for example in a preferred embodiment R is
 t-butyloxycarbonyl, m and n are each 0 or 1, their sum being
 at least 1; R¹ is cyclohexylmethyl; R² is 2-methylpropyl,
 2-methyl-2-propenyl, benzyl, 4-chlorobenzyl, 3-chlorobenzyl,
 4-methylbenzyl, 4-methoxybenzyl, 3,4-dichlorobenzyl,
 2-chlorobenzyl or cyclohexylmethyl; R³ is hydrogen; R⁴ is
 hydrogen, methyl, 4-aminobutyl, 2-carboxyethyl,
 3-(ethoxycarbonyl)propyl or 3-(benzyloxycarbonyl)-propyl;
 W is phenylalanyl, W¹ is histidyl and W² is lysyl.

These compounds are useful for inhibiting the an-
 giotensinogen cleaving action of the enzyme renin having
 particular utility in the treatment of hypertension.



European Patent
Office

EUROPEAN SEARCH REPORT

0212903

Application number

EP 86 30 5995

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
X	EP-A-0 045 665 (M. SZELKE) * Page 10, lines 16-32 * --	10,14	C 07 K 5/06 C 07 K 5/02 C 07 K 1/00
X,Y	WO-A-84 03 044 (FERRING AB) * Whole document * --	1-3,8, 10-15	C 07 C 125/065 C 07 C 129/12 C 07 D 307/62 A 61 K 37/62
Y	EP-A-0 081 783 (MERCK) * Page 7, lines 13-18; page 14, lines 1-3 * --	1-3,8, 10,11	
Y	PEPTIDES, STRUCTURE AND FUNCTION, Proc. of the 9th Am. Peptide Symp., Toronto, June 1985, pages 4615-4625; Pierce Chem. Co., Rockford, US B.E. EVANS et al.: "A stereocon- trolled synthesis of hydroxyethyle- ne dipeptide isosteres using novel, chiral aminoalkyl epoxides; new renin inhibitor analogs" * Whole article * --	12-15 11	
A			
Y	J. MED. CHEM., vol. 26, 1983, pages 1457-1462; Am. Chem. Soc., US R.L. JOHNSON et al.: "Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydro- xy-7-methyloctanoic acid" * Page 1458 * -- ./.	12-15	
XX			
Place of search		Date of completion of the search	Examiner
THE HAGUE		07-08-1989	HERMANN
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons Δ : member of the same patent family, corresponding document	



European Patent
Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid.
- namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

X LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions.

namely:

1. Claims 8,11 and 1-3,10,12-15 partially:
Renin inhibitory peptides for the formula on page 87, lines 2-8, as far as n and m are each 1, and R¹ is cyclohexylmethyl. Intermediates and processes for their preparation.
2. Claims 12-15 partially:
Stereospecific processes and intermediates for the preparation of further peptide derivatives of the formula on page 87, lines 2-8.
3. Claims 4-7,9 and 1-3,10 partially:
Peptide derivatives of the formula on page 87, lines 2-8, and their protected C-terminal moieties (claim 10, page 90, lines 19-23), as far as not covered by the scope of subject 1.

NOTE: This subject still contains a wide range of very different compounds, for which the search authority could not distinguish unifying inventive concepts. A search for this subject would have resulted in further non-unity objections.

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☒ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.

namely claims: 8,11-15 and 1-3,10 partially

- ☐ None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.

namely claims:

